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Abstract 
Introduction: It is still controversial whether borderline lesions with a vulnerable
plaque should be stented early or simply treated pharmacologically. No data
exist concerning the potential effects of statin therapy on borderline vulnerable
lesions in patients with acute coronary syndrome (ACS).
Material and methods: Fifty patients with ACS whose culprit lesions were
classified as “borderline lesions” were enrolled. All patients were treated with
atorvastatin (20 mg) for 12 months. Intravascular ultrasound (IVUS) was
performed and matrix metalloproteinase-9 (MMP-9), tissue inhibitor of
metalloproteinase-1 (TIMP-1), and high-sensitive C-reactive protein (hsCRP) levels
were measured at baseline and 12-month follow-up.
Results: At 12-month follow-up, we found: 1) IVUS revealed that minimal lumen
cross-sectional area (CSA) increased but plaque/media (P&M) area and plaque
burden decreased. A total of 25 soft plaques (50%) were transformed into fibrous
plaques. 2) ApoB, MMP-9 and hsCRP levels decreased, but TIMP-1 level increased.
3) Stepwise multivariate linear regression analysis showed that the independent
predictors for changes in P&M area/year were the decrease in MMP-9 and hsCRP
levels. 
Conclusions: Atorvastatin therapy stabilized borderline vulnerable plaques and
reversed atherosclerosis progression in patients with ACS. Reversal of this
progression was accompanied by a decrease in the levels of plasma MMP-9 and
hsCRP . Changes in MMP-9 and hsCRP could predict vulnerable plaque
stabilization.
Key words: intravascular ultrasound, atorvastatin, acute coronary syndrome,
vulnerable plaque.
Introduction 
The pathological mechanisms of acute coronary syndrome (ACS) are
based on thrombosis secondary to unstable plaque rupture [1]. In many
cases, less than 70% of local stenosis of the culprit lesions (lesions directly
responsible for the ischaemia episode) is detected by coronary angiography
(CAG) [2, 3]. At present, the threshold for clinical revascularization therapy
is 70% narrowing [4]. Interventional guidelines of CAD (ACC/AHA 2005)
[5] assign those with less than 50% narrowing as Class III, indicating
whether angina does or does not exist. It is still controversial whether
borderline lesions with a vulnerable plaque should be stented early or only
treated pharmacologically. Statins improve the long-term prognosis of
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Copyright © 2011 Termedia & Banachpatients with coronary artery disease due to plaque
stabilization [6]. There are no reports on the
frequency of new events caused by progression of
borderline lesions in patients with ACS. Evidence
suggests that there are no differences between
mechanical and pharmacological stabilization of
borderline coronary lesions in patients with ACS [7].
The present study prospectively investigates the
effect of atorvastatin therapy on borderline
vulnerable lesion progression with serial intra  -
vascular ultrasound (IVUS) in patients with ACS.
Material and methods
Study population
From May 2007 to December 2008, we enrolled
50 patients with ACS (based on typical symptoms,
ECG changes and elevated cardiac troponin T level
> 0.1 ng/dl) admitted to the Cardiac Unit in
Guangdong Cardiovascular Institute. According to
the AHA/ACC guidelines for ACS [5], all patients were
treated after admission with antiplatelet and other
therapies including angiotensin-converting enzyme
inhibitors/angiotensin II receptor blockers, β-blockers
and statins. Twenty-two of these patients had
received statin therapy prior to admission.
Atorvastatin (20 mg) was prescribed to all patients
as statin therapy for 12 months. Inclusion criteria for
these lesions were an angiographic lumen diameter
stenosis 50~70% termed borderline lesions,
a minimal lumen cross-sectional area ≥ 4.0 mm2 by
IVUS, and lesions located in 1 of 3 major epicardial
arteries where stent implantation was not
performed. When > 1 lesion/patient was studied,
the lesion with the larger plaque burden was
selected for this study. Culprit lesions were identified
by a combination of ECG and CAng. Exclusion criteria
included severe calcified lesions and patients with
acute ST-elevated acute myocardial infarction
(STEMI) where reperfusion strategy is the treatment
of choice. Measurements of chemical indicators
were altered by acute inflammation or infection,
pregnancy or contraindications to therapy with
atorvastatin. During the 12-month follow-up,
occurrence of major adverse cardiac events, such as
acute myocardial infarction (creatine kinase-MB
fraction increased to 3 times the upper limit of
normal), target lesion revascularization (percu  -
taneous or surgical inter  vention of lesions), or death
from any cause was evaluated. This study was
performed with the patients’ written informed
consent and approval of the institutional review
board. Changes in lipid profiles were calculated at
baseline and at 12-month follow-up.
Selective coronary angiography
Selective CAG was performed according to the
standard Judkins technique [8]. Before CAG,
nitroglycerine (200 μg) was injected into the
coronary artery to prevent vessel spasm. Vessel
diameters were determined with a 6 F angiographic
catheter used as a scaling device. Quantitative
coronary analysis was performed using the Digital
Cardiac Imaging (DCI) system. 
Intravascular ultrasound imaging and analysis
Baseline and 12-month follow-up IVUS
examination of culprit lesions were performed in
the same manner after intracoronary admi  -
nistration of nitroglycerine (200 μg) with a moto  -
rized trans  ducer pull-back system (0.5 mm/s) and
a com  mercial scanner (Boston Scientific Corp./
SCIMED, Natick, Massachusetts), consisting of
a rotating 40-MHz transducer with a 2.9 Fr
imaging sheath. Intravascular ultrasound images
were recorded using the iLab ultrasound imaging
system. Quantitative and qualitative analyses
were performed according to the criteria of the
clinical expert consensus document on IVUS [9]
while quantitative IVUS analysis was performed
using computerized planimetry (Boston Scientific
iReview 1.0 Software). All of these analyses were
independently performed by an experienced
analyst who was blinded to the lesion and patient
background. On playback of the baseline and 
12-month follow-up IVUS studies, matching image
slices were acquired at 3 different sites of the
culprit lesions: the segment with the narrowest
lumen cross-sectional area (CSA) and sites 2 mm
proximal and distal to the narrowest segment.
Quantitative measurements included the external
elastic membrane (EEM) CSA, lumen CSA and
plaque and media (P&M = external elastic
membrane – lumen) CSA. Plaque burden was
calculated as the P&M area divided by the EEM
CSA. Changes in IVUS measurements between
baseline and 12-month follow-up were deter  -
mined.
Sample measurements
Blood samples were acquired on admission and
at the end of follow-up. Commercially available
ELISA kits were used for measurement of matrix
metalloproteinase-9 (MMP-9; human MMP-9 ELISA,
Bender MedSystems Inc), tissue inhibitor of
metalloproteinase-1 (TIMP-1) (human TIMP-1 ELISA,
Bender MedSystems Inc) and high-sensitive C-
reactive protein (hsCRP, hsCRP ELISA, Bender
MedSystems Inc).
Statistical analysis
Statistical analyses were performed using SPSS
13.0 software. Data are presented as frequencies
or mean ± SD. Comparison was performed with a χ2
test or paired Student’s t test. Multivariate stepwise
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regression analyses were performed to determine
the independent predictors of change in annual
changes of P&M cross-sectional area. A p < 0.05
(two-tailed) was considered significant. 
Results
Demographic and baseline characteristics 
This study involved 50 patients (39 male, 
11 female) aged 44-76 years (mean 63.8 ±10.9 years)
with ~50 culprit lesions. Hypertension was found
in 32 patients (64%) and type 2 diabetes mellitus
in 8 patients (16%). Twenty-nine patients (58%)
were smokers. Two patients had previous
myocardial infarction and 1 patient had a family
history of coronary heart disease. Thirty-eight
lesions (73.1%) were located at the anterior
descending artery, 8 lesions (15.4%) at the
circumflex and 6 (11.5%) at the right coronary artery.
Two-vessel disease was found in 2 patients.
Lipid profile
Apolipoprotein B (ApoB) levels decreased
significantly at follow-up compared with baseline.
Levels of other lipoproteins showed minimal change
(Table I).
Coronary angiography and intravascular
ultrasound data
At 12-month follow-up, CAG showed little change
in diameter stenosis (62.50 ±10.21% vs. 54.79
±12.35%, p = 0.48) and area stenosis (58.61 ±8.36%
vs. 48.18 ±10.56%, p = 0.78). Minimal lumen CSA
increased (p < 0.01), P&M area decreased, and
plaque burden decreased (p < 0.01) at 12-month
follow-up. Soft plaques transformed into fibrous
plaques in 25 cases, indicating stabilization of the
plaques (Table II, Figures 1, 2).
Changes in plasma matrix metalloproteinase-9,
tissue inhibitor of metalloproteinase-1 and
high-sensitive C-reactive protein
Plasma MMP-9 and hsCRP decreased signi  -
ficantly, while plasma TIMP-1 levels increased
significantly (Table III).
Clinical follow-up
There were no adverse events reported during
the following-up period.
Relationship between plaque changes and
plasma matrix metalloproteinase-9, tissue
inhibitor of metalloproteinase-1 and high-
sensitive C-reactive protein levels
The mean annual change in P&M area was 1.34
±0.97 mm2/year. Using a stepwise regression model,
annual change in MMP-9, annual change in 
TIMP-1 and annual change in hsCRP were the inde  -
pendent variables, while annual change in P&M
area was the dependent variable. The regression
equation was: annual change in P&M area = –1.327
±0.003, annual change in MMP-9 ±0.344, annual
change in hsCRP, R2 = 0.830, adjusted R2 = 0.819, 
F = 78.152, p = 0.000 (Figure 3). 
Discussion
Although patients with ACS can benefit from
revascularization, medical therapy is the basis for
their treatment. Atherosclerosis affects not only
the culprit lesion but the whole coronary artery
tree [10, 11]. As the most important agents in the
TC [mmol/l] LDL-C [mmol/l] HDL-C [mmol/l]T G  [mmol/l]A p oA1 [g/l]A p oB [g/l]
Baseline 4.10 ±0.89 1.83 ±0.59 1.12 ±0.25 1.83 ±1.50 1.21 ±0.26 0.68 ±0.13
Follow-up 3.85 ±0.96 1.91 ±0.61 1.12 ±0.19 1.55 ±1.27 1.10 ±0.16 0.59 ±0.14 
Value of p NS NS NS NS NS < 0.05
TC – total cholesterol, LDL-C – low-density lipoprotein cholesterol, HDL-C – high-density lipoprotein cholesterol, TG – triglyceride, 
ApoA1 – apolipoprotein A-I, ApoB – apolipoprotein B
Table I. Lipid profile at baseline and at follow-up
EEM CSA Minimal  P&M  Plaque  Soft  Fibrous Coronary  Plaque
[mm2] lumen CSA area Burden plaque plaque thrombus rupture
[mm2][ mm2] [%] n (%) n (%) n (%) n (%)
Baseline 13.79 ±3.19 5.63 ±2.51 8.17 ±2.55 61.41 ±10.34 43 (86.0%)  5 (10.0%) 7 (20%) 5 (14%)
Follow-up 14.07 ±2.10 6.32 ±2.42 7.70 ±2.19 56.94 ±8.47 18 (36.0%) 30 (60.0%) 0 (0%) 0 (0%)
Value of p NS < 0.01 < 0.05 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
CSA – cross-sectional area, EEM – external elastic membrane, P&M area – plaque and media cross-sectional area 
Table II. Intravascular ultrasound imaging at baseline and follow-up436 Arch Med Sci 3, June / 2011
secondary prevention of coronary artery disease,
statins have many pleiotropic effects on the
cardiovascular system, including effects on
endothelial cells, smooth muscle cells, leukocytes,
and platelets [12]. Due to the “pleiotropic” effects
of a reduction in inflammation, intensive statin
therapy beginning soon after ACS provides a rapid
early reduction in clinical events [13]. Many studies
have shown that intensive statin therapy could
contribute to reversing atherosclerosis progression
[14, 15]. By reducing inflammation and improving
endothelial function, statins promote plaque
stability and prevent ACS [16]. We propose that
statins could also stabilize vulnerable lesions in
ACS and reverse their progression. This may
influence the strategy used in treatment of
borderline vulnerable lesions.
In the ESTABLISH [17] trial, a randomized open
clinical trial in Japan, 70 patients with ACS received
atorvastatin 20 mg daily for 6 months, resulting in
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Figure 1. A – plaque area change. B – minimal lumen
cross-scetional area change. C – plaque burden
change at baseline and follow-up
Figure 2. Representative 3-dimensional intravascular ultrasound analysis at both baseline and follow-up. A – IVUS
imaging at baseline. B – IVUS imaging at follow-up
M
e
a
n
A
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Baseline Follow-up
p = 0.004
M
e
a
n
C
8
6
4
2
0
Baseline Follow-up
p = 0.001
M
e
a
n
B
AB
Dan-Qing Yu, Shu-Guang Lin, Ji-Yan Chen, Ling Xue, Guang Li, Hao-Jian Dong, Ying-Ling ZhouArch Med Sci 3, June / 2011 437
Atorvastatin and Borderline Vulnerable Lesions
a reduction of 13.1% in plaque volume. In contrast,
an increase of 8.7% was observed in the control
group. The present study also demonstrated that
treatment with 20 mg of atorvastatin daily resulted
in an increase in minimal lumen CSA as well as
a decrease in P&M area. These data support daily
administration of 20 mg atorvastatin for inhibition
of plaque progression in Asian populations.
The primary goal of lipid-lowing treatment and
the importance of low-density lipoprotein choles  -
terol (LDL-C) as the predictor for coronary events
has been emphasized in various guidelines [18, 19].
In the present study, we administered atorvastatin
20 mg daily to patients whose LDL-C levels were at
a lower level (LDL-C = 1.83 ±0.59 mmol/l) prior to
enrolment. After 12 months on atorvastatin, there
was no significant change in the LDL-C level.
However, for borderline vulnerable lesions, minimal
lumen CSA increased, P&M area decreased, and
plaque burden decreased. Furthermore, soft plaques
in 25 cases changed to fibrous plaques, indicating
stabilization of the plaque. These findings
demonstrated that the benefits of atorvastatin
therapy for atherosclerosis progression may not be
related to LDL-C lowering. 
Several studies have focused on lipoproteins
other than LDL-C. Long-term prospective studies
showed that apolipoprotein A-I (ApoA1), ApoB and
the ApoB/ApoA1 ratio correlated with the risk of
atherosclerotic cardiovascular disease better than
the levels of total cholesterol (TC), low-density
lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C) and triglyceride (TG)
[20, 21]. Compared with TC/HDL-C and HDL-C/ 
LDL-C, the ApoB/ApoA1 ratio is a more powerful
predictor of risk of a coronary event among
untreated patients [22, 23]. For patients who have
been previously treated with a statin, LDL-C levels
lose their predictive strength but the levels of ApoB
and ApoB/A1 work the same way as in untreated
patients [23-25]. 
In the present study, after 12 months on
atorvastatin, there were no significant changes in
LDL-C. We believe this finding to be attributable to
the following factors: 1) 22 patients received statin
therapy prior to admission, which was a very high
ratio (44%). Since most of these patients’ lipid levels
did not change between baseline and follow-up,
this high ratio will affect the statistical results even
after atorvastatin therapy. 2) The lipid levels of our
patients were lower relative to baseline. Therefore,
the lipid levels may not change significantly even
after atorvastatin therapy at follow-up. 3) The lipid
levels of most Chinese patients were low to
moderate. However, there was a sharp reduction in
ApoB after 12 months. ApoB is found in lipoproteins
originating from the liver [very low-density
lipoprotein (VLDL), intermediate density lipoprotein
(IDL), LDL] and is the primary apolipoprotein
component for lipoproteins with the exception of
HDL [26]. ApoB acts as a ligand for lipoprotein
receptors in various cells throughout the body, thus
playing an important role in atherosclerosis. The
significance of the sharp reduction in ApoB in the
present study remains unclear. It may suggest
a possible reduction in very-low density lipoprotein
cholesterol (VLDL-C). Decreases in the level of ApoB
Figure 3. A – relationship between plaque changes and changes in the levels of plasma MMP-9. B – relationship
between plaque changes and changes in the levels of plasma hs-CRP
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MMP-9 TIMP-1 hsCRP
[ng/ml][ ng/ml][ mg/l]
Baseline 2192 ±881 657 ±247 3.48 ±1.50
Follow-up 1773 ±1085 709 ±227 0.39 ±0.19
Value of p < 0.01 < 0.01 < 0.01
MMP-9  – matrix metalloproteinase-9, TIMP-1 – tissue inhibitor of
metalloproteinase-1, hsCRP – high-sensitive C-reactive protein
Table III. Levels of MMP-9, TIMP-1, and hsCRP at
baseline and follow-up
R2 linear = 0.676438 Arch Med Sci 3, June / 2011
may have direct or indirect effects on plaque
stability. 
Inflammation also plays an important role in
ACS progression. Imbalance in the MMPs
contributes to plaque instability. Yip et al. [27] and
Nomoto et al. [28] demonstrated that an increase
in hsCRP is positively related to unstable plaque
rupture in local arteries. The present study also
showed that the levels of plasma MMP-9 and
hsCRP were higher and TIMP-1 was lower
following ACS compared with those after 12
months of treatment. Multivariate stepwise
regression analyses revealed that decreases in the
levels of MMP-9 and hsCRP were positively
correlated with the reversion of athero  sclerosis
progression. The effect of atorvastatin on reversal
of atherosclerotic progression was accompanied
by changes in the level of inflam  matory markers.
Therefore, detection of changes in the levels of
MMP-9 and hsCRP may provide guidance in
monitoring plaque progression and making
treatment decisions. 
Coronary angiography has long been
considered the “gold standard” in diagnosing
coronary artery disease [29]. Unlike CAG, which
displays the coronary artery as a silhouette of the
contrast-filled lumen, IVUS is a new diagnostic
technique that provides unique information
concerning arterial wall structure and luminal
dimensions. Intravascular ultrasound reveals the
severity and eccentric nature of the plaque lesions,
which may be under  esti  mated in angiographic
measurements. Intravascular ultrasound also
provides insights into the extent of the lipid-rich
plaques, calcification and thickness of the fibrous
cap, providing valuable information. De Scheerder
et al. [30] found that for borderline lesions
detected by CAG, the correlation between IVUS
and quantitative CAG data was very weak. Studies
by Nishioka et al. [31] and Abizaid et al. [32] sup  -
ported an IVUS minimum luminal CSA < 4.0 mm2
as a criterion for defining significant stenoses in
proximal vessels. Therefore, the present study
provided medical therapy for borderline vulnerable
lesions without coronary intervention. The ability
of atorvastatin to stabilize such lesions defined
by CAG and IVUS simultaneously in patients with
ACS was confirmed. 
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